Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genta Begins Treatment In Tesetaxel Phase 2 Trial
The company said that as a late Phase 2 oncology product, Tesetaxel is the leading oral taxane currently in clinical development. Unlike standard Taxanes (paclitaxel [Taxol] or Docetaxel
The company said that as a late Phase 2 oncology product, Tesetaxel is the leading oral taxane currently in clinical development. Unlike standard Taxanes (paclitaxel [Taxol] or Docetaxel
The Lighthouse Probe can be used for real-time monitoring of chemical and pharmaceutical processes and provides in-process window cleaning, recalibration during the process, full CIP (cleaning) of wash
With the introduction of ClearFoil X and ClearFoil Z, clear ultra-high barrier packaging options can now replace aluminum foil structures for those very demanding applications. The company claims
Denzapine is indicated in treatment resistant schizophrenic patients and in schizophrenia patients who have severe, untreatable neurological adverse reactions to other antipsychotic agents, including atypical antipsychotics. The company
The FDA had a thorough inspection of the Naroda facility and cleared after it was found to be suitable for manufacturing export-purpose APIs. The facility is an Export
Earlier, on April 16, 2008, Pfizer and Celldex Therapeutics (Celldex) have entered into an agreement to grant Pfizer an exclusive worldwide license to PF-04948568 (CDX-110) which is currently
Preliminary clinical data from the first 24 weeks of the study (12 weeks at 0.1mg/kg and 12 weeks at 1.0mg/kg) have been evaluated. BioMarin plans to announce top-line
The company has initiated its phase IIb clinical trial for CVac in the US, under the auspices of the FDA, and intends to start recruitment of patients shortly.
As per the agreement, Tecan will industrialise and deliver manufactured ML instruments for Enigma’s global market supplies for an initial five-year contract, and will also manage the ML
The clinical candidate is a new class of agent containing three separate RNAi elements, simultaneously targeting three different sites of the hepatitis C virus, and encapsidated in an